These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32379270)

  • 1. Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancer-Fact or Fiction?
    Corcoran RB; Grothey A
    JAMA Oncol; 2020 Jun; 6(6):823-824. PubMed ID: 32379270
    [No Abstract]   [Full Text] [Related]  

  • 2. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neoadjuvant immunotherapy in microsatellite stability or mismatch repair proficient colorectal cancer].
    Zhang JW; Deng YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):193-198. PubMed ID: 35340167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues.
    Sahin IH; Ciombor KK; Diaz LA; Yu J; Kim R
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-12. PubMed ID: 35658496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The Efficacy of Immune Checkpoint Inhibitors as First-line Treatment in Microsatellite-instability-high Metastatic Colorectal Cancer].
    Lee JY
    Korean J Gastroenterol; 2021 May; 77(5):261-262. PubMed ID: 34035206
    [No Abstract]   [Full Text] [Related]  

  • 6. Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.
    Overman MJ; Ernstoff MS; Morse MA
    Am Soc Clin Oncol Educ Book; 2018 May; 38():239-247. PubMed ID: 30231358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for Colorectal Cancer.
    Mukherji R; Weinberg BA; Pedersen KS
    Hematol Oncol Clin North Am; 2022 Jun; 36(3):603-626. PubMed ID: 35577706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer.
    Liang T; Tong W; Ma S; Chang P
    Oncoimmunology; 2020 Jun; 9(1):1773205. PubMed ID: 32934878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Will Immune Checkpoint Inhibitors Allow the Non-operative Management of Mismatch Repair-deficient Colorectal Cancer to Become a Standard of Care?
    Sinclair H; Ranji T; Gilbert DC
    Clin Oncol (R Coll Radiol); 2024 Mar; 36(3):136-140. PubMed ID: 38245479
    [No Abstract]   [Full Text] [Related]  

  • 10. Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer.
    Ludford K; Cohen R; Svrcek M; Foo WC; Colle R; Parc Y; Thomas JV; Morris VK; Kopetz S; Chang GJ; Overman M; Andre T
    J Natl Cancer Inst; 2021 Feb; 113(2):208-211. PubMed ID: 32294214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microsatellite instability and mismatch repair genes in colorectal cancer: useful tools for managing patients and counseling their relatives.
    Douillard JY
    Clin Colorectal Cancer; 2010 Oct; 9(4):193-4. PubMed ID: 20920989
    [No Abstract]   [Full Text] [Related]  

  • 12. [Microsatellite instability (MSI): best predictor of effectiveness of immune checkpoint inhibitors (ICKi)? Focus on MSI by Bulletin du Cancer].
    André T
    Bull Cancer; 2019 Feb; 106(2):91-93. PubMed ID: 30711199
    [No Abstract]   [Full Text] [Related]  

  • 13. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
    Kather JN; Halama N; Jaeger D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer.
    Meltzer S; Negård A; Bakke KM; Hamre HM; Kersten C; Hofsli E; Guren MG; Sorbye H; Flatmark K; Ree AH
    Br J Cancer; 2022 Dec; 127(12):2227-2233. PubMed ID: 36229579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors.
    Xicola RM; Llor X; Pons E; Castells A; Alenda C; Piñol V; Andreu M; Castellví-Bel S; Payá A; Jover R; Bessa X; Girós A; Duque JM; Nicolás-Pérez D; Garcia AM; Rigau J; Gassull MA;
    J Natl Cancer Inst; 2007 Feb; 99(3):244-52. PubMed ID: 17284719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden].
    Cohen R; Heran M; Pudlarz T; Hilmi M; Tournigand C; André T; Rousseau B
    Bull Cancer; 2019 Feb; 106(2):151-161. PubMed ID: 30638897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Could the immune checkpoint inhibitor against colorectal cancer in constitutional mismatch repair deficiency syndrome prevent new cancer formation?
    Tanimura K; Yamasaki K; Matsubara K; Noguchi M; Kikuchi N; Nitani C; Okada K; Fujisaki H; Okuno T; Inoue T; Nebiki H; Akagi K; Tomita N; Hara J
    Pediatr Blood Cancer; 2022 Jan; 69(1):e29312. PubMed ID: 34453473
    [No Abstract]   [Full Text] [Related]  

  • 18. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population.
    Ito T; Kono K; Eguchi H; Okazaki Y; Yamamoto G; Tachikawa T; Akagi K; Okada Y; Kawakami S; Morozumi M; Tamaru JI; Ishida H
    Jpn J Clin Oncol; 2020 Jan; 50(1):80-88. PubMed ID: 31665498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.